HomeAll ContractsContract
NON-GMP SYNTHESIS OF GALIDESIVIR MONO-, DI-, AND TRIPHOSPHATE (BCX6870)
Total Committed
$368K
Product or Service Description
Biomedical R&D
Contracting Agency
Effective Date
July 14, 2021
Funding Department
NATIONAL INSTITUTES OF HEALTH NIAID
Type
Firm fixed price
Solicitation Procedure
Subject to multiple award fair opportunity
Extent Competed
Full and open competition

Recent Contract Actions

Contracts can have multiple “contract actions”: This is how agencies spend money for a specific purpose, adjust the amount committed or change the contract in a way that doesn’t affect the amount. That last scenario is usually indicated by a $0 action. If there is a contract action for a negative amount, it generally means the contract was adjusted or canceled.

Vendor Description Signed Reason for Change Amount Committed
EUROFINS PANLABS, INC. NEW AWARD E-09 July 14, 2021 $133,500
EUROFINS PANLABS, INC. THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE QUANTITY OPTIONS 1A-1J FOR SCREENING OF RODENT PHARMACOKINETICS FOR LEAD OPTIMIZATION. Nov. 13, 2020 Exercise An Option $86,400
EUROFINS PANLABS, INC. NON-GMP SYNTHESIS OF GALIDESIVIR MONO-, DI-, AND TRIPHOSPHATE (BCX6870) July 20, 2020 Other Administrative Action $0
EUROFINS PANLABS, INC. TO PROVIDE NON-GLP STANDARD, INITIAL PROFILING OF LEAD COMPOUNDS IN RODENT PHARMACOKINETICS (PK) SCREENING ASSAYS TO PROVIDE IMPORTANT DATA FOR SELECTION OF THE MOST PROMISING LEAD SERIES AS WELL AS PROVIDE DATA FOR IN VITRO-IN VIVO CORRELATION OF AS July 10, 2020 $129,600
EUROFINS PANLABS, INC. NON-GMP SYNTHESIS OF GALIDESIVIR MONO-, DI-, AND TRIPHOSPHATE (BCX6870) June 10, 2020 $18,273
About this data
This data comes from the Federal Procurement Data System, which includes all contracts worth $10,000 or more. We look at all contracts that are tagged with the procurement code for COVID-19 or otherwise started in 2020 and contain “COVID-19” in the description. Department of Defense contracting data is subject to a 90-day delay before it appears in the data.
Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page